Mechanical ventilation is associated with significant short-and long-term morbidity in small preterm infants. Continuous positive airway pressure applied through nasal prongs is an effective, less-invasive method to improve gas exchange and reduce apnea in these infants. A large number of studies have evaluated the possibility of reducing the need or duration of mechanical ventilation by early use of nasal continuous positive airway pressure shortly after birth and by applying it after extubation. Although results of these trials have not been consistent, most of the evidence suggests that nasal continuous positive airway pressure is a viable alternative to mechanical ventilation in many preterm infants and that its use after extubation contributes to maintain better lung function and reduces apnea. Despite this, there is no evidence that these beneficial short-term effects translate into lower rates of long-term morbidity such as bronchopulmonary dysplasia and neurologic sequelae or mortality rates.
Introduction
Despite the advent of new strategies to prevent and treat respiratory distress such as prenatal steroids and surfactant therapy, bronchopulmonary dysplasia (BPD) remains a major complication in preterm infants and its incidence has not changed significantly during the last decade. 1 The pathogenesis of BPD is closely linked to the use of mechanical ventilation in the immature lung. Therefore, strategies to minimize the lung injury associated with mechanical ventilation, such as nasal continuous positive airway pressure (NCPAP), could lower the incidence of BPD. Several studies, mostly retrospective in nature, have suggested that the use of early continuous positive airway pressure (CPAP) may be associated with a decrease in lung damage and in the incidence of BPD.
Mechanical ventilation can damage the immature lung by over distension produced by excessive tidal volume because of excessive peak inspiratory pressure or prolonged inspiratory time, excessive positive end-expiratory pressure (PEEP) or trapped gas, insufficient functional residual capacity (FRC) because of low PEEP, oxygen toxicity and inadequate conditioning of the inspired gas temperature and humidity. In addition, when the airway is invaded with an endotracheal tube, there is an increased risk of airway colonization and infection with pathogens. Therefore, the use of CPAP can protect against the development of BPD by avoiding the need of mechanical ventilation and by reducing the risk of bacterial colonization via the endotracheal tube. 2 Why use CPAP Since its introduction in 1971, CPAP has generally been accepted as one of the more significant advances in the management of infants with respiratory distress syndrome (RDS). Numerous studies have demonstrated the effectiveness of distending airway pressure in improving oxygenation. 3 The effects of CPAP includes an increase in FRC, thus improving PaO 2 , decreasing airway resistance, reducing obstructive apnea, 4, 5 and stabilizing the chest wall and reducing its distortion. However, with excessive CPAP, PaCO 2 may increase as tidal volume decreases and dead space increases. Excessive CPAP may also reduce lung compliance and lead to airleak syndromes. In addition, by increasing intrathoracic pressure, it may reduce venous return to the right heart and depress cardiac output. The devices used to deliver NCPAP may produce skin excoriation and nasal damage, leading to obstruction and risk of infection.
Continuous positive airway pressure has been used for many years primarily to treat preterm infants with surfactant deficiency. In 1971, Gregory et al. 6 first demonstrated that the use of CPAP improved oxygenation in newborns with respiratory distress. This observation was followed by prospective studies that demonstrated improved survival in premature infants treated with early CPAP. 7, 8 Initial studies demonstrated that the early use of CPAP in premature infants <1500 g birth weight led to the need for reduced FiO 2 and a milder clinical course.
A review of prospective studies evaluating early CPAP in the presurfactant and pre-antenatal steroid era concluded that the use of early CPAP for respiratory distress improved survival in infants with birth weight over 1500 g. 2 Until now however, there are no definitive studies and no clinical consensus regarding the best approach to minimize ventilator-associated lung injury in extremely low birth weight (ELBW) infants. Strategies vary from early delivery room surfactant administration and intermittent mandatory ventilation to early delivery room CPAP, in an attempt to avoid surfactant and intubation. CPAP is increasingly seen as a viable alternative to intubation and mechanical ventilation for the treatment of respiratory distress in ELBW infants.
Indications for the use of CPAP CPAP as an alternative to mechanical ventilation for respiratory failure There is an emerging body of literature suggesting that early CPAP can reduce the need for intubation and mechanical ventilation in a significant number of very low birth weight (VLBW) infants. Reports from Europe suggest that when compared with historical controls, the introduction of CPAP decreases the need for intubation [10] [11] [12] and the incidence of BPD.
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Another retrospective study from New Zealand reported that after the introduction of CPAP in 1996, the need for mechanical ventilation decreased from 65% in the previous years to 14% and the incidence of BPD from 11 to 0% in infants with a birth weight between 1000 and 1500 g. 14 One prospective observational uncontrolled study concluded that prophylactic CPAP starting at birth may be effective in most infants above 25 weeks gestational age and less than 1500 g birth weight, in which the need for mechanical ventilation was less than 30% after early treatment with NCPAP. 15 Furthermore, two retrospective studies demonstrating a decrease in the incidence of BPD in institutions with a high use of CPAP have encouraged the idea of using CPAP as an alternative to mechanical ventilation. A classic survey by Avery et al. 16 from eight North American neonatal intensive care units suggested that early use of CPAP could be associated with a lower incidence of BPD. A more recent comparison of practices and outcomes of infants born with birth weights of 500-1500 g in two neonatal units at the University of Harvard and one at Columbia University revealed that while initial CPAP was used in 63% of cases at Columbia compared to 11% at the Harvard Centers, the rate of BPD was substantially lower at Columbia compared with the Harvard centers (4 vs 22%). 17 These reports reflect the variation in criteria for intubation and the use of mechanical ventilation among institutions. Furthermore, comparisons between centers and between infants in different eras are confounded by variations in the characteristics of the patients entering treatment programs and co-interventions such as the use of antenatal steroids and surfactants. The introduction of CPAP may appear very beneficial when introduced in a population with low BPD risk who may not need mechanical ventilation. In this situation, lung damage may be a consequence of the needless use of mechanical ventilation.
Further research into the use of CPAP as an alternative to intubation and mechanical ventilation must address two important considerations: the optimal time for the application of CPAP and the need for the administration of surfactant.
CPAP prophylaxis vs treatment
The term prophylaxis implies the use of nasal CPAP commencing soon after birth in VLBW premature infants regardless of the respiratory status of the infant, compared to the more conventional methods of treatment where CPAP is used for a defined respiratory condition not requiring immediate intubation.
Two retrospective studies showed both a decrease in the need for mechanical ventilation 18 and a decrease in the incidence of BPD 19 with the introduction of early CPAP in the delivery room. However, a meta-analysis by Subramaniam et al., 20 which evaluated the only prospective randomized trial, 21 showed no benefits in the infants receiving early nasopharyngeal CPAP (NP-CPAP). A feasibility pilot study by the NIH network, in which early CPAP in the delivery room was used for infants less 28 weeks gestational age, showed that while NCPAP could be initiated early, it did not prevent the need for intubation in most infants and 80% of them were intubated during the 7 days after birth. 22 Recent data from Columbia University demonstrates a CPAP failure rate of 50% in premature infants <700 g birth weight. 23 Sixty-seven percent of these infants were intubated during the first 72 h of life. This study failed to identify reliable early predictors of CPAP failure. 23 The latest controlled, randomized, multicenter study carried out in infants of more than 28 weeks gestation did not show benefits from initiating CPAP as prophylaxis vs rescue therapy in these larger infants. 24 Early CPAP with surfactant Intubation and surfactant administration are traumatic events and may be potentially destabilizing to a very premature infant. On the other hand, early administration of surfactant at birth may be more effective than treatment after decompensation has occurred. Therefore, delayed intubation and ventilation can be associated with clinical deterioration and poorer response to surfactant administration.
A prospective evaluation comparing early intubation for the administration of surfactant followed by NCPAP vs NCPAP alone was stopped after an interim analysis demonstrated a clear benefit to the infants receiving early surfactant. 25 A later trial from the same group confirmed a reduced need for mechanical ventilation (68 vs 25%) in infants <30 weeks gestational age requiring no ventilatory support other than supplemental oxygen and NCPAP initially, when treated with early surfactant and NCPAP vs latesurfactant treated infants. 26 A prospective study conducted by Thompson, 27 published only in abstract form, compared early NCPAP with intermittent positive pressure ventilation (IPPV) combined with prophylaxis vs rescue surfactant in both arms. The study demonstrated a decrease in the need for mechanical ventilation in the first 5 days after birth in infants in the early NCPAP group. There were no differences within the early NCPAP group when surfactant was given as a prophylaxis or as a treatment. No differences were found in oxygen dependence at either 28 days or 36 weeks between infants treated with IPPV or NCPAP.
In a recent study, infants of 25-28 weeks gestational age were randomized after receiving surfactant to NCPAP or mechanical ventilation. The use of surfactant and NCPAP decreased the need for mechanical ventilation from 100% in the control group to 62% in the NCPAP group. 28 Similar results were published by Dani et al. 29 showing a lesser need for mechanical ventilation in patients who after administration of surfactant were randomized to NCPAP vs mechanical ventilation.
A recent study in larger infants (29-35 weeks gestational age) showed a decreased need for mechanical ventilation after the administration of prophylactic surfactant and rapid extubation to NCPAP vs NCPAP alone. Other secondary outcomes like duration of mechanical ventilation or oxygen therapy were not different. 30 These studies suggest that surfactant replacement therapy coupled with NCPAP in the early stages of RDS seems more effective than NCPAP alone.
NCPAP to decrease the duration of mechanical ventilation
A number of studies have evaluated the efficacy of NCPAP after extubation to avoid failure to extubate and the need for reintubation. Most of these studies demonstrated a beneficial effect of NCPAP on respiratory function and the prevention of atelectasis after extubation. 31, 32 In a randomized controlled trial comparing oxyhood with NCPAP after extubation, NCPAP was more effective in preventing respiratory failure in premature infants <1000 g birth weight. Successful extubation was defined as remaining free of additional ventilatory support for at least 5 days (76% in the NCPAP group vs 21% in the oxyhood group).
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A meta-analysis of several studies conducted to evaluate the effectiveness of NCPAP in facilitating extubation demonstrated NCPAP to be effective in preventing failure of extubation in preterm infants following a period of endotracheal intubation and mechanical ventilation, 34 but it did not reduce the need for reintubation. The most recent study to examine the use of NCPAP after extubation also showed no reduction in the need of reintubation and ventilation when compared with direct extubation to an oxygen hood. 35 However, in this study, NCPAP was used only for 24 h after extubation.
Currently, many premature infants who receive antenatal steroids and surfactant are extubated but then need to be reintubated because of apnea. 36 Apnea and bradycardia are the most common causes of failure after extubation in VLBW infants. Nasal continuous positive airway pressure is effective in reducing the incidence of apnea in these infants by opening the upper airway and preventing obstructive apnea. 37, 38 It may also improve FRC by stabilizing the chest wall and reducing the work of breathing. 39 What is the best system to deliver NCPAP To deliver NCPAP effectively, it requires a team effort and experience with the device that is being used. To maintain an infant on NCPAP is clearly more demanding in nursing time and effort than keeping them on a mechanical ventilator. To succeed with NCPAP, it is important to use the correct size prongs, to position the neck properly and to provide frequent suction to keep the airway clear of secretions and to closely observe the breathing pattern. An orogastric tube open to atmosphere should be placed to prevent abdominal distension. Regarding the nasal device, evidence from meta-analyses of randomized clinical trials suggests that short binasal devices are more effective in preventing reintubation because they offer lower resistance. 40 Studies investigating different ways of delivering CPAP (bubble vs continuous flow) found no differences in alveolar ventilation or blood gases between these methods. 41, 42 A recent study compared the use of the infant flow driver vs conventional ventilator and nasal prongs, and concluded that the infant flow driver was as effective as conventional CPAP in preventing extubation failure in small premature infants. 43 Synchronized nasal intermittent positive pressure ventilation (NIPPV) Nasal intermittent positive pressure ventilation (NIPPV) is a mode of non-invasive respiratory assistance that combines NCPAP with superimposed ventilator breaths. It is an accepted mode for weaning infants from mechanical ventilation and for the treatment of apnea in premature newborns. A recent meta-analysis showed that NIPPV is superior to NCPAP in preventing failure after extubation. 44 More recently, a prospective observational study concluded that infants extubated to NIPPV needed both a shorter duration of intubation and less oxygen as compared to those who were maintained on conventional ventilation. 45 There have been some case reports of gastrointestinal perforation, but none when the ventilator breaths are synchronized with the infant's inspiratory effort.
Conclusions
Nasal continuous positive airway pressure can be used to prevent extubation failure in preterm infants and to reduce the duration of mechanical ventilation when this is required for apnea. The NCPAP is effective in the management of RDS in preterm infants and can be used safely from the time of birth in the delivery room.
The use of NCPAP appears to be more effective in decreasing the need for mechanical ventilation when used after the administration of surfactant shortly after birth. The most important question as to whether the use of early NCPAP is associated with a reduction in BPD without worsening neurological outcome remains to be answered.
Although NIPPV is emerging as an effective non-invasive alternative for the management of respiratory distress, no controlled studies have been published testing its use as a first-line therapy.
